Human respiratory syncytial virus medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
[[Category:Mononegavirales]] | [[Category:Mononegavirales]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Infectious disease]] | |||
[[Category:Pediatrics]] | |||
[[Category:Pulmonology]] | |||
[[Category:Disease]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 20:13, 10 December 2012
Human respiratory syncytial virus Microchapters |
Differentiating Human Respiratory Syncytial Virus from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Human respiratory syncytial virus medical therapy On the Web |
American Roentgen Ray Society Images of Human respiratory syncytial virus medical therapy |
Human respiratory syncytial virus medical therapy in the news |
Directions to Hospitals Treating Human respiratory syncytial virus |
Risk calculators and risk factors for Human respiratory syncytial virus medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
Ribavirin, a broad-spectrum antiviral agent, was once employed as adjunctive therapy for the sickest patients; however, its efficacy has been called into question by multiple studies, and most institutions no longer use it.
Treatment is otherwise supportive care only with fluids and oxygen until the illness runs its course.